04:09:45 Europe / Stockholm

Svenska | English

Lytix Biopharma

Kalender

2023-11-09	Kvartalsrapport 2023-Q3
2023-08-31	Kvartalsrapport 2023-Q2
2023-05-11	Kvartalsrapport 2023-Q1
2023-04-19	Ordinarie utdelning LYTIX 0.00 NOK
2023-04-18	Årsstämma 2023
2023-02-16	Bokslutskommuniké 2022
2022-11-17	Kvartalsrapport 2022-Q3
2022-08-25	Kvartalsrapport 2022-Q2
2022-05-12	Kvartalsrapport 2022-Q1
2022-04-22	Ordinarie utdelning LYTIX 0.00 NOK
2022-04-21	Årsstämma 2022
2022-02-17	Bokslutskommuniké 2021

Beskrivning

Land	Norge
Lista	MERK Equities
Sektor	Hälsovård
Industri	Bioteknik

Lytix Biopharma är ett bioteknikbolag i kliniskt stadium som utvecklar nya cancerimmunterapier. Bolagets teknik bygger på forskning inom antimikrobiella peptider, ett försvar riktade mot patogener. Lytix Biopharmas huvudprodukt, LTX-315, är en onkolytisk peptid med syftet att personalisera immunterapi. Bolaget bedriver sin forskning och verksamhet i Oslo, Norge.

Filter

År

Typ

Språk

Rensa

2023-11-09 08:00:00 LYTIX: Lytix Biopharma presents third quarter 2023 results -5,80% | 0,47 MNOK

2023-11-08 12:00:00 LYTIX: Lytix Biopharma presenting at major investor conferences in London and Stockholm in November +4,55% | 0,33 MNOK

2023-11-02 08:00:00 Lytix Biopharma: Presentation of third quarter 2023 results, November 9 0,00% | 0,54 MNOK

2023-10-25 13:23:26 LYTIX: Financial calendar +1,52% | 0,62 MNOK

2023-10-23 08:00:00 LYTIX: Encouraging preliminary data from Lytix Biopharma's ATLAS-IT-05 study presented at ESMO 2023 -4,79% | 0,80 MNOK

2023-10-20 09:00:00 LYTIX: Lytix Biopharma to host webcast after release of preliminary data from ATLAS-IT-05 +3,55% | 1,67 MNOK

2023-10-17 08:00:00 LYTIX: Lytix Biopharma granted up to NOK14.3m (US$1.3m) of public non-dilutive funding from 'SkatteFUNN' -2,14% | 0,51 MNOK

2023-10-16 08:51:55 LYTIX: Lytix Biopharma's abstract with preliminary interim Phase II data from the ATLAS-IT-05 study is published -1,41% | 0,21 MNOK

2023-10-09 15:00:00 LYTIX: Neoadjuvant study with LTX-315 in early-stage melanoma patients to be presented at the 15th Nordic melanoma meeting -1,54% | 1,08 MNOK

2023-08-31 08:00:00 LYTIX: Lytix Biopharma presents first half and second quarter 2023 results -1,56% | 0,19 MNOK

2023-08-28 13:48:13 LYTIX: Lytix Biopharma announces completion of patient recruitment in the ATLAS-IT-05 trial -4,95% | 2,16 MNOK

2023-08-24 08:00:00 Lytix Biopharma: Presentation of second quarter 2023 results, August 31 -4,17% | 0,30 MNOK

2023-08-11 08:00:00 LYTIX: Lytix Biopharma's licensing partner Verrica Pharmaceuticals Inc. reports interim Phase II data with LTX-315 +8,59% | 5,11 MNOK

2023-08-03 14:37:17 LYTIX: Lytix Biopharma announces that Verrica Pharmaceuticals Inc. will present clinical results from their ongoing Phase II clinical study with LTX-315 (VP-315) at the 2023 American Academy of Dermatology Association's Innovation Academy meeting +7,69% | 0,08 MNOK

2023-07-20 08:00:00 LYTIX: Lytix Biopharma announces presentation of interim data from ATLAS-IT-05 study at ESMO 2023 +1,43% | 0,02 MNOK

2023-06-21 22:49:15 Lytix Biopharma AS: GRANT OF SHARE OPTIONS -8,28% | 0,18 MNOK

2023-05-25 08:00:00 LYTIX: Lytix Biopharma to present at ABG Sundal Collier Life Science Summit and Redeye Growth Day in Stockholm +4,71% | 0,29 MNOK

2023-05-11 08:00:00 LYTIX: Lytix Biopharma presents first quarter 2023 results -8,96% | 0,59 MNOK

2023-05-04 08:00:00 Lytix Biopharma: Presentation of first quarter 2023 results, Thursday 11 May +3,82% | 0,08 MNOK

2023-05-03 07:55:34 LYTIX: Lytix Biopharma to present at the 'Frontiers in Cancer Immunotherapy 2023', invited by New York Academy of Sciences 0,00% | 0,01 MNOK

2023-04-19 08:01:31 LYTIX: Lytix Biopharma appoints new Chairman of the Board +0,76% | 0,04 MNOK

2023-04-18 16:50:19 Lytix Biopharma AS: GRANT OF SHARE OPTIONS +0,76% | 0,04 MNOK

2023-04-18 16:46:10 Lytix Biopharma - Minutes of Ordinary General Meeting +0,76% | 0,04 MNOK

2023-04-11 10:17:32 Lytix Biopharma AS: Notice of Annual General Meeting on 18 April 2023 +10,61% | 0,43 MNOK

2023-03-30 08:00:00 Lytix Biopharma: Annual Report for 2022 +6,77% | 0,02 MNOK

2023-02-16 08:00:00 LYTIX: Lytix Biopharma presents fourth quarter and second half 2022 results +2,62% | 1,02 MNOK

2023-02-09 08:00:00 Lytix Biopharma: Invitation to presentation of fourth quarter and second half 2022 results, Thursday 16 February -7,86% | 0,01 MNOK

2022-12-15 15:08:14 LYTIX: Financial calendar -9,41% | 0,25 MNOK

2022-12-15 15:08:14 LYTIX: Finansiell kalender -9,41% | 0,25 MNOK

2022-12-14 19:15:05 Lytix Biopharma AS: GRANT OF SHARE OPTIONS -9,41% | 0,25 MNOK

2022-11-17 08:00:00 LYTIX: Lytix Biopharma third quarter 2022 results -7,05% | 0,20 MNOK

2022-11-14 08:00:00 LYTIX: Lytix Biopharma announces expansion of the ATLAS-IT-05 study to Europe -0,22% | 0,02 MNOK

2022-11-10 14:00:00 LYTIX: Lytix Biopharma presents compelling data in collaboration with research groups at National Cancer Institute and Weill Cornell Medicine, USA. -1,36% | 0,02 MNOK

2022-11-10 08:00:00 Lytix Biopharma: Invitation to presentation of third quarter 2022 results, Thursday 17 November -1,36% | 0,02 MNOK

2022-11-01 15:25:16 LYTIX: Invitation to Capital Markets Day in Oslo, November 22, 2022 +6,97% | 0,03 MNOK

2022-10-20 13:54:06 Lytix Biopharma to host Capital Markets Day - November 22, 2022 0,00% | 0,00 MNOK

2022-10-05 14:52:11 LYTIX: Lytix Biopharma announces that an abstract has been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting -0,24% | 0,03 MNOK

2022-09-29 11:23:33 LYTIX: Financial calendar +1,14% | 0,00 MNOK

2022-09-07 08:00:00 LYTIX: Lytix Biopharma announces approval to expand the ATLAS-IT-05 study to Europe +10,02% | 0,13 MNOK

2022-09-05 08:00:06 LYTIX: Lytix Biopharma appoints Stephen Worsley as Chief Business Officer -8,29% | 0,26 MNOK

2022-09-01 18:41:45 Lytix Biopharma: Mandatory notification of trade +14,65% | 0,29 MNOK

2022-08-27 12:48:26 LYTIX: Mandatory notification of trade -6,46% | 0,41 MNOK

2022-08-26 15:06:48 Lytix Biopharma: Mandatory notification of trade +24,03% | 1,56 MNOK

2022-08-25 07:59:38 Lytix Biopharma: Second quarter and first half of 2022 results +0,56% | 0,12 MNOK

2022-08-18 09:00:00 Lytix Biopharma: Invitation to presentation of first half and second quarter 2022 results, Thursday August 25th, 2022 +1,52% | 0,04 MNOK

2022-06-05 15:00:00 LYTIX: Lytix Biopharma AS announces that LTX-315 in combination with Adoptive Cell Therapy has been shown to generate tumor-specific T cells and stabilize the disease in patients with progressive metastatic soft tissue sarcoma (STS) +1,01% | 0,47 MNOK

2022-05-27 08:00:00 LYTIX: Lytix Biopharma AS announces that an abstract on LTX-315 in combination with Adoptive Cell Therapy is selected for a poster presentation at ASCO 2022 -8,82% | 0,11 MNOK

2022-05-19 16:41:08 Lytix Biopharma - Invitation to Capital Markets Day in Oslo, June 1, 2022 +0,20% | 0,14 MNOK

Visa fler

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Lytix Biopharma

Kalender

Beskrivning

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden